TCGA-BH-A0BR-01A-21R-A115-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 78
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.630
- ANGIOGENESIS+0.440
- COAGULATION+0.440
- NOTCH_SIGNALING+0.440
- APICAL_JUNCTION+0.420
- INFLAMMATORY_RESPONSE+0.400
- COMPLEMENT+0.390
- HEDGEHOG_SIGNALING+0.390
- TNFA_SIGNALING_VIA_NFKB+0.390
- KRAS_SIGNALING_UP+0.380
Top 10 suppressed
- MYC_TARGETS_V2-0.440
- MYC_TARGETS_V1-0.410
- DNA_REPAIR-0.330
- OXIDATIVE_PHOSPHORYLATION-0.330
- E2F_TARGETS-0.290
- G2M_CHECKPOINT-0.230
- INTERFERON_ALPHA_RESPONSE-0.120
- KRAS_SIGNALING_DN-0.110
- ESTROGEN_RESPONSE_EARLY-0.080
- PANCREAS_BETA_CELLS-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BA-5557-01A-01R-1514-07 | — | — | 0.911 |
| 2 | TCGA-43-6647-01A-11R-1820-07 | — | cohortSQ1 | 0.894 |
| 3 | TCGA-64-5815-01A-01R-1628-07 | — | cohortA1 | 0.884 |
| 4 | TCGA-BH-A0B7-01A-12R-A115-07 | — | C | 0.883 |
| 5 | TCGA-CN-4742-01A-02R-1514-07 | — | — | 0.878 |
| 6 | SRR1516079 | — | — | 0.876 |
| 7 | TCGA-DK-A1AF-01A-11R-A13Y-07 | — | — | 0.874 |
| 8 | TCGA-CR-6477-01A-11R-1873-07 | — | — | 0.874 |
| 9 | MBCProject_0065_T1_RNA | — | C | 0.865 |
| 10 | TCGA-73-4658-01A-01R-1755-07 | — | cohortA1 | 0.864 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.630 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.440 | Remibrutinib | — uncovered |
| COAGULATION | 0.440 | Binimetinib | — uncovered |
| NOTCH_SIGNALING | 0.440 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.420 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| COMPLEMENT | 0.390 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.390 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.390 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.380 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.370 | Temsirolimus | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.360 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.340 | Inavolisib | — uncovered |
| HYPOXIA | 0.340 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.320 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.320 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.320 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.310 | Inavolisib | — uncovered |
| APOPTOSIS | 0.310 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.290 | Remibrutinib | — uncovered |